|William J. Craigen, MD, PhD||Executive Leadership|
|Annette Feigenbaum, MD||Executive Committee|
|Jenny Goldstein, PhD, CGC||Executive Committee|
|Uta Lichter-Konecki, MD||Executive Committee|
|Amanda Thomas, PhD||Executive Committee|
|Diane Zastrow, MS||Executive Committee|
|Meredith Weaver PhD, ScM, CGC||Coordinator|
Please contact a coordinator if you have questions.
A systematic process of evaluating evidence to classify a genomic variant on a spectrum from pathogenic to benign with respect to a particular disease and inheritance pattern.